[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obstructive-hypertrophic-cardiomyopathy-ohcm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obstructive-hypertrophic-cardiomyopathy-ohcm":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,66,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100635808","mavacamten-outcomes-in-hypertrophic-cardiomyopathy-hcm-and-the-associated-patient-and-physician-experiences-in-the-us-100635808",false,"NCT07557498","Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US","Mavacamten Real-World OutcomeS and the Associated PAtient and Physician ExpeRienCe With Hypertrophic CardioMyopathy in the United States (US) Community","SPARC-HCM","Inclusion Criteria:\n\nPhase I: retrospective chart review\n\nFor inclusion in the study, participants must meet ALL of the following criteria:\n\n* Are an adult aged 18 or over at baseline\n* Have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (HCM)\n* Have been prescribed mavacamten for obstructive HCM at one of the study sites between 28th April 2022 and 31st December 2024\n* Have not ever been enrolled in any interventional clinical trial involving any cardiac myosin inhibitor (enrollment in observational studies is permitted)\n* Are not enrolled in any interventional clinical trial at study baseline\n\nPhase II: patient survey • Participants must meet all inclusion criteria of Phase I: retrospective chart review and be able to read and understand English and have access to computer or smartphone to complete the survey\n\nExclusion Criteria:\n\n• None with the proviso that all inclusion criteria are met.","ALL","18 Years",{"count":20,"type":21},362,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice",[25],"Obstructive Hypertrophic Cardiomyopathy (oHCM)",[27],"Obstructive Hypertrophic cardiomyopathy (oHCM)","RECRUITING","2026-04-23",{"date":31,"type":32},"2026-04-29","ACTUAL",{"date":34,"type":32},"2026-01-15",{"date":36,"type":21},"2027-06-17",{"name":38,"class":39},"Bristol-Myers Squibb","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100621215","phase-2-ademetionine-in-obstructive-hypertrophic-cardiomyopathy-100621215","NCT07367724","Ademetionine in Obstructive Hypertrophic Cardiomyopathy","Safety and Efficacy of Ademetionine in Patients With Obstructive Hypertrophic Cardiomyopathy: A Multicenter, Double-Blind, Randomized Controlled, Phase 2 Study","Inclusion Criteria:\n\n* Meet the diagnostic criteria for HCM.\n* Age ≥ 18 years at screening.\n* LVEF ≥ 50% at screening.\n* Echocardiography demonstrates a resting or provoked LVOTG ≥ 30 mmHg at screening.\n* NYHA Functional Class II-III at screening.\n* Able to perform CPET.\n* Patients receiving treatment with β-blockers or non-dihydropyridine calcium channel blockers should have been on a stable dose for at least 6 weeks prior to randomization and are expected to maintain the same medication during the trial. Who have previously received cardiac myosin inhibitors (e.g., Mavacamten) must discontinue the treatment for at least 8 weeks prior to randomization.\n* Willing and able to sign the informed consent form and comply with all scheduled study visits.\n\nExclusion Criteria:\n\n* History of severe hypersensitivity to any component of Ademetionine 1,4-Butanedisulfonate Enteric-coated Tablets.\n* History of psychiatric disorders, or current use of antidepressants such as clomipramine.\n* Planned for any surgical (including septal reduction therapy) or interventional procedure during the trial period.\n* Planned use of cardiac myosin inhibitors (e.g., Mavacamten) during the trial period.\n* Currently pregnant or planning pregnancy.\n* Currently participation in another drug or device clinical trial.\n* History of any other disease with a life expectancy of less than 1 year.",{"count":49,"type":21},44,"INTERVENTIONAL",[52],"PHASE2","This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM). The study will recruit patients with oHCM who, under double-blind conditions, will be randomly assigned to either the Ademetionine group or the placebo group. Follow-up visits will be conducted every 4 weeks until 16 weeks from baseline. After 16 weeks, the study will evaluating the effect of Ademetionine on exercise capacity, heart failure symptoms, cardiac structure and function, and quality of life, as well as safety and tolerability of Ademetionine in this patient population.",[25],"2026-03-18",{"date":57,"type":32},"2026-03-20",{"date":59,"type":32},"2026-01-01",{"date":61,"type":21},"2027-12-31",{"name":63,"class":64},"China National Center for Cardiovascular Diseases","OTHER_GOV",3,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":75,"conditions":76,"keywords":77,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":65},"100626770","biological-collection-for-the-purpose-of-exploring-genetic-and-clinical-biological-factors-associated-with-variability-in-response-to-mavacamten-in-the-treatment-of-obstructive-hypertrophic-cardiomyopathy-100626770","NCT07439952","Biological Collection for the Purpose of Exploring Genetic and Clinical-biological Factors Associated With Variability in Response to Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy","MAVA PG","Inclusion Criteria:\n\n* \\- Patients aged ≥18 years\n* Diagnosis of obstructive hypertrophic cardiomyopathy (OHCM), based on the guidelines of the European Society of Cardiology (Arbelo et al. 2023), with unexplained left ventricular hypertrophy and a maximum LVOT gradient ≥ 50 mmHg at rest, or after Valsalva manoeuvre or exercise at the time of diagnosis, and an LVOT gradient with Valsalva manoeuvre ≥ 30 mmHg at selection\n* With cardiac symptoms defined as NYHA class II\u002FIII, persistent despite background treatment (beta-blockers or calcium channel blockers)\n* LVEF ≥55% at the start of treatment with mavacamten\n* Initiation of treatment with mavacamten or patient already receiving treatment\n* Prescription of pre-treatment CYP2C19 genotyping performed\n* Consent to participate signed by the patient\n* Beneficiary of health insurance\n\nExclusion Criteria:\n\n* Minors\n* Adults under guardianship (legal guardianship and curatorship) or judicial protection\n* Pregnant or breastfeeding women",{"count":74,"type":21},300,"The European Medicines Agency has required pre-treatment genotyping of CYP2C19 to determine the initial and maximum dosage, in order to avoid overexposure to mavacamten associated with a decrease in ventricular ejection fraction below 50% in slow metabolisers of CYP2C19 (AUC multiplied by 3.4). The study is a requalification for the search for DNA samples obtained during treatment in order to genotype the genes of interest.The primary objective of the study is to estimate, for each of the CYP2C19 phenotypes of interest determined by genotyping (ultra-rapid, rapid, normal\u002Fextensive and intermediate metabolisers), the proportion of patients who are non-responders to mavacamten at each time point (D0, Week 4, Week 8, Week 12 and Week 24 in the treatment of HCM). This is a multicentre (3 centres which are hospitals of APHP) study aiming to include 300 patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten who underwent or are undergoing CYP2C19 genotyping at the start of treatment. The inclusion period is 36 months and the follow-up period is 6 months. The total duration of the study is 42 months.",[25],[78,79,80],"mavacamten","obstructive hypertrophic cardiomyopathy","polymorphisms of CYP2C19, CYP3A4\u002FCYP3A5 and CYP2C9","NOT_YET_RECRUITING","2026-02-26",{"date":84,"type":32},"2026-02-27",{"date":86,"type":21},"2026-02-05",{"date":88,"type":21},"2029-07",{"name":90,"class":91},"Assistance Publique - Hôpitaux de Paris","OTHER",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":40},"100622392","mavacamten-post-marketing-surveillance-in-patients-with-obstructive-hypertrophic-cardiomyopathy-in-japan-100622392","NCT07383025","Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan","Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy (oHCM) in Japan","Inclusion Criteria:\n\n• All obstructive hypertrophic cardiomyopathy (oHCM) patients who initiate treatment with Mavacamten of the approved indications at medical institutions in Japan during enrollment period will be enrolled in this regulatory post-marketing surveillance (PMS) study\n\nExclusion Criteria:\n\n• Participants receiving Mavacamten for an off-label indication will be excluded from this PMS study",{"count":100,"type":21},200,"The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan",[25],[104],"Obstructive hypertrophic cardiomyopathy (oHCM)","2026-01-26",{"date":107,"type":32},"2026-02-03",{"date":109,"type":32},"2025-05-21",{"date":111,"type":21},"2029-11-30",{"name":38,"class":39}]